Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hisashi Wada

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
NY-ESO-1 expression and immunogenicity in esophageal cancerShoichiro Fujita, Hisashi Wada, Achim A Jungbluth, et al.
Nature Communications|December 15, 2021
Depletion of central memory CD8<sup>+</sup> T cells might impede the antitumor therapeutic effect of MogamulizumabYuka Maeda, Hisashi Wada, Daisuke Sugiyama, et al.
Nature Communications|April 8, 2026
PD-1 antibody-bound progenitor-exhausted CD8<sup>+</sup> T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancerYohei Nose, Yoshiaki Yasumizu, Takuro Saito, et al.
International Journal of Cancer|February 6, 2007
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patientsRyohei Kawabata, Hisashi Wada, Midori Isobe, et al.
International Journal of Cancer|August 30, 2008
Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccinationHisashi Wada, Eiichi Sato, Akiko Uenaka, et al.
Esophagus : Official Journal of the Japan Esophageal Society|April 24, 2025
Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable/recurrent esophageal squamous cell carcinomaShigeto Nakai, Tomoki Makino, Kota Momose, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2022
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patientsKentaro Jingushi, Atsunari Kawashima, Takuro Saito, et al.
International Journal of Cancer|March 31, 2011
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigenKazuhiro Kakimi, Midori Isobe, Akiko Uenaka, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2017
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLCTomohira Takeoka, Hirotsugu Nagase, Koji Kurose, et al.
Cancer Science|November 20, 2024
Bacterial information in serum extracellular vesicles reflects the inflammation of adherent perinephric fatToshihiro Uemura, Atsunari Kawashima, Kentaro Jingushi, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
NY-ESO-1 expression and immunogenicity in esophageal cancerShoichiro Fujita, Hisashi Wada, Achim A Jungbluth, et al.
Nature Communications|December 15, 2021
Depletion of central memory CD8<sup>+</sup> T cells might impede the antitumor therapeutic effect of MogamulizumabYuka Maeda, Hisashi Wada, Daisuke Sugiyama, et al.
Nature Communications|April 8, 2026
PD-1 antibody-bound progenitor-exhausted CD8<sup>+</sup> T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancerYohei Nose, Yoshiaki Yasumizu, Takuro Saito, et al.
International Journal of Cancer|February 6, 2007
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patientsRyohei Kawabata, Hisashi Wada, Midori Isobe, et al.
International Journal of Cancer|August 30, 2008
Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccinationHisashi Wada, Eiichi Sato, Akiko Uenaka, et al.
Esophagus : Official Journal of the Japan Esophageal Society|April 24, 2025
Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable/recurrent esophageal squamous cell carcinomaShigeto Nakai, Tomoki Makino, Kota Momose, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2022
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patientsKentaro Jingushi, Atsunari Kawashima, Takuro Saito, et al.
International Journal of Cancer|March 31, 2011
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigenKazuhiro Kakimi, Midori Isobe, Akiko Uenaka, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 25, 2017
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLCTomohira Takeoka, Hirotsugu Nagase, Koji Kurose, et al.
Cancer Science|November 20, 2024
Bacterial information in serum extracellular vesicles reflects the inflammation of adherent perinephric fatToshihiro Uemura, Atsunari Kawashima, Kentaro Jingushi, et al.
Pageof 10